Literature DB >> 35165171

Striatal Indirect Pathway Dysfunction Underlies Motor Deficits in a Mouse Model of Paroxysmal Dyskinesia.

Alexandra B Nelson1,2,3,4, Allison E Girasole5,2,3,4, Hsien-Yang Lee2, Louis J Ptáček5,2,3,4, Anatol C Kreitzer1,2,6,3,4,7.   

Abstract

Abnormal involuntary movements, or dyskinesias, are seen in many neurologic diseases, including disorders where the brain appears grossly normal. This observation suggests that alterations in neural activity or connectivity may underlie dyskinesias. One influential model proposes that involuntary movements are driven by an imbalance in the activity of striatal direct and indirect pathway neurons (dMSNs and iMSNs, respectively). Indeed, in some animal models, there is evidence that dMSN hyperactivity contributes to dyskinesia. Given the many diseases associated with dyskinesia, it is unclear whether these findings generalize to all forms. Here, we used male and female mice in a mouse model of paroxysmal nonkinesigenic dyskinesia (PNKD) to assess whether involuntary movements are related to aberrant activity in the striatal direct and indirect pathways. In this model, as in the human disorder PNKD, animals experience dyskinetic attacks in response to caffeine or alcohol. Using optically identified striatal single-unit recordings in freely moving PNKD mice, we found a loss of iMSN firing during dyskinesia bouts. Further, chemogenetic inhibition of iMSNs triggered dyskinetic episodes in PNKD mice. Finally, we found that these decreases in iMSN firing are likely because of aberrant endocannabinoid-mediated suppression of glutamatergic inputs. These data show that striatal iMSN dysfunction contributes to the etiology of dyskinesia in PNKD, and suggest that indirect pathway hypoactivity may be a key mechanism for the generation of involuntary movements in other disorders.SIGNIFICANCE STATEMENT Involuntary movements, or dyskinesias, are part of many inherited and acquired neurologic syndromes. There are few effective treatments, most of which have significant side effects. Better understanding of which cells and patterns of activity cause dyskinetic movements might inform the development of new neuromodulatory treatments. In this study, we used a mouse model of an inherited human form of paroxysmal dyskinesia in combination with cell type-specific tools to monitor and manipulate striatal activity. We were able to narrow in on a specific group of neurons that causes dyskinesia in this model, and found alterations in a well-known form of plasticity in this cell type, endocannabinoid-dependent synaptic LTD. These findings point to new areas for therapeutic development.
Copyright © 2022 the authors.

Entities:  

Keywords:  basal ganglia; dyskinesia; dystonia; endocannabinoid; striatum; synaptic plasticity

Mesh:

Substances:

Year:  2022        PMID: 35165171      PMCID: PMC8973425          DOI: 10.1523/JNEUROSCI.1614-20.2022

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  90 in total

1.  RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits.

Authors:  Talia N Lerner; Anatol C Kreitzer
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

Review 2.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

Review 3.  Primate models of movement disorders of basal ganglia origin.

Authors:  M R DeLong
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

4.  Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.

Authors:  Ledia F Hernández; Ivan Castela; Irene Ruiz-DeDiego; Jose A Obeso; Rosario Moratalla
Journal:  Mov Disord       Date:  2017-03-03       Impact factor: 10.338

5.  Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.

Authors:  Philippe Damier; Stéphane Thobois; Tatiana Witjas; Emmanuel Cuny; Philippe Derost; Sylvie Raoul; Patrick Mertens; Jean-Claude Peragut; Jean-Jacques Lemaire; Pierre Burbaud; Jean-Michel Nguyen; Pierre-Michel Llorca; Olivier Rascol
Journal:  Arch Gen Psychiatry       Date:  2007-02

6.  Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus.

Authors:  R Dayne Mayfield; G Larson; R A Orona; N R Zahniser
Journal:  Synapse       Date:  1996-02       Impact factor: 2.562

7.  Cell-Type-Specific Control of Brainstem Locomotor Circuits by Basal Ganglia.

Authors:  Thomas K Roseberry; A Moses Lee; Arnaud L Lalive; Linda Wilbrecht; Antonello Bonci; Anatol C Kreitzer
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

8.  The neural substrates of rapid-onset Dystonia-Parkinsonism.

Authors:  D Paola Calderon; Rachel Fremont; Franca Kraenzlin; Kamran Khodakhah
Journal:  Nat Neurosci       Date:  2011-02-06       Impact factor: 24.884

9.  Acute cerebellar knockdown of Sgce reproduces salient features of myoclonus-dystonia (DYT11) in mice.

Authors:  Samantha Washburn; Rachel Fremont; Maria Camila Moreno-Escobar; Chantal Angueyra; Kamran Khodakhah
Journal:  Elife       Date:  2019-12-23       Impact factor: 8.140

10.  Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.

Authors:  Barbara Picconi; Diego Centonze; Kerstin Håkansson; Giorgio Bernardi; Paul Greengard; Gilberto Fisone; M Angela Cenci; Paolo Calabresi
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.